John Militello - 14 Aug 2023 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role: VP, Principal Accounting Officer and Interim Principal Financial Officer
Signature: /s/ Martin Wilson, as attorney-in-fact for John Militello
Issuer symbol: RCKT
Transactions as of: 14 Aug 2023
Net transactions value: $0
Form type: 4
Filing time: 15 Aug 2023, 16:17:08 UTC
Previous filing: 24 Jul 2023
Next filing: 21 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RCKT	Common Stock	Options Exercise	$0	+725	+10%	$0.000000	7,854	14 Aug 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RCKT	Restricted Stock Units	Options Exercise	$0	-725	-14%	$0.000000	4,353	14 Aug 2023	Common Stock	725		Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of Common Stock received upon vesting of a restricted stock unit ("RSU") award.
F2	Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3	One-third (1/3) of such RSUs became fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.

Remarks:

VP, Principal Accounting Officer and Interim Principal Financial Officer